This article only represents the author's own views.
A victory in head-to-head clinical trials has the power to shake up the pharmaceutical industry, where companies are competing to deliver the next game-changing drug.
Which is why China’s TYK Medicines Inc. (2410.HK) grabbed the sector spotlight this month when it announced that a drug under development had outperformed the world’s leading lung cancer treatment in early trials. Investors wondered if they were witnessing the arrival of a new disruptor in the market for cancer therapies.
您已閱讀10%（541字），剩余90%（4664字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。